Stock Quote
OSI Pharmaceuticals, Inc. (OSIP.O) (Nasdaq)
$32.90
12:20pm EST
+0.34%
$32.79
$32.88
170,778
$33.06
$32.84
$43.00
$27.01
0.72
567,426
OSIP.O
More News
| Press Releases
| Key Developments
| Name | Current Position | Compensation |
|---|---|---|
| Ingram, Robert | Chairman of the Board | -- |
| Goddard, Colin | Chief Executive Officer, Director | 2,794,806 |
| Legault, Pierre | Chief Financial Officer, Executive Vice President, Treasurer | 149,766 |
Profile
OSI Pharmaceuticals, Inc. (OSI) is a biotechnology company primarily focused on the discovery, development and commercialization of molecular targeted therapies addressing unmet medical needs in oncology, diabetes and obesity. The Company's primary focus is oncology and its flagship product is... Full Description
Company Address
OSI Pharmaceuticals, Inc.
41 Pinelawn Road
Melville NY 11747
P: +1631.9622000
41 Pinelawn Road
Melville NY 11747
P: +1631.9622000
Analyst Research
Performance of Key Competitors
| Company | Price | Change |
|---|---|---|
| Genentech, Inc. | -- | -- |
| Roche Holding Ltd. | CHF166.20 | +3.50 |
| Roche Holding Ltd. | CHF169.10 | +1.80 |
| OSIP.O | Industry | |
|---|---|---|
| P/E(TTM) | 5.15 | 12.80 |
| P/S(TTM) | 4.73 | 29.90 |
| ROI(TTM) | 46.78 | 2.35 |
| ROE(TTM) | 93.22 | 3.59 |
| Consensus Recommendation | Outperform |
|---|---|
| EPS Est. (Current Period) | 0.46 |
| EPS Est. (Current Year) | 1.36 |
| Total Revenue | $111.45M |
| Net Income | $17.86M |
| EPS | $0.30 |
